ERBB2 and non-small cell lung carcinoma: Additionally, the FDA has granted accelerated approval for T-DXd in the treatment of metastatic HER2-mutant non-small cell lung cancer (NSCLC) [50] and breakthrough therapy designations for treating patients with HER2-positive metastatic colorectal cancer (mCRC) and advanced HER2-positive solid tumors [51, 52].